Johannes vom Berg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4352287/publications.pdf Version: 2024-02-01



IOHANNES VOM REPC

#	Article	IF	CITATIONS
1	New insights into IL-12-mediated tumor suppression. Cell Death and Differentiation, 2015, 22, 237-246.	11.2	373
2	Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline. Nature Medicine, 2012, 18, 1812-1819.	30.7	359
3	IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46. Nature Immunology, 2010, 11, 1030-1038.	14.5	188
4	Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection. Journal of Experimental Medicine, 2013, 210, 2803-2811.	8.5	177
5	A βPix–Pak2a signaling pathway regulates cerebral vascular stability in zebrafish. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13990-13995.	7.1	107
6	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Frontiers in Oncology, 2018, 8, 285.	2.8	89
7	Enzymatic Dissociation Induces Transcriptional and Proteotype Bias in Brain Cell Populations. International Journal of Molecular Sciences, 2020, 21, 7944.	4.1	72
8	Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. European Journal of Pharmacology, 2019, 854, 398-405.	3.5	53
9	Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Science Translational Medicine, 2021, 13, eabc8188.	12.4	48
10	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. Clinical Cancer Research, 2019, 25, 5890-5900.	7.0	31
11	Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer. , 2022, 10, e004044.		19
12	Microglia-Centered Combinatorial Strategies Against Glioblastoma. Frontiers in Immunology, 2020, 11, 571951.	4.8	17
13	Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. Cancers, 2021, 13, 785.	3.7	15
14	T cell-specific inactivation of mouse CD2 by CRISPR/Cas9. Scientific Reports, 2016, 6, 21377.	3.3	11
15	Bone marrow chimeras—a vital tool in basic and translational research. Journal of Molecular Medicine, 2019, 97, 889-896.	3.9	9
16	In Vivo Imaging of Hypoxia-Inducible Factor Regulation in a Subcutaneous and Orthotopic GL261 Glioma Tumor Model Using a Reporter Gene Assay. Molecular Imaging, 2014, 13, 7290.2014.00029.	1.4	8
17	<scp>OMIPâ€065</scp> : Dog Immunophenotyping and Tâ€Cell Activity Evaluation with a 14â€Color Panel. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 1024-1027.	1.5	8
18	Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery. Journal of Visualized Experiments, 2019, , .	0.3	7

JOHANNES VOM BERG

#	Article	IF	CITATIONS
19	Expression analysis data of BCL11A and γ-globin genes in KU812 and KG-1Âcell lines after CRISPR/Cas9-mediated BCL11A enhancer deletion. Data in Brief, 2020, 28, 104974.	1.0	6
20	Enabling comprehensive optogenetic studies of mouse hearts by simultaneous opto-electrical panoramic mapping and stimulation. Nature Communications, 2021, 12, 5804.	12.8	6
21	A ribonucleoprotein transfection strategy for CRISPR/Cas9â€mediated gene editing and single cell cloning in rainbow trout cells. Cell and Bioscience, 2021, 11, 103.	4.8	5
22	De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. Oncogene, 2022, 41, 1507-1517.	5.9	3
23	SCDT-41. IN VIVO TESTING OF INTRACRANIAL DELIVERY OF RECOMBINANT HUMAN IL-12 AND IL-12Fc AND FUNCTIONAL ASSESSMENT ON HUMAN, PORCINE AND CANINE PERIPHERAL BLOOD MONONUCLEAR CELLS. Neuro-Oncology, 2017, 19, vi273-vi273.	1.2	0
24	Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors. European Journal of Cancer, 2018, 92, S19.	2.8	0
25	Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor – Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models. European Journal of Cancer, 2018, 92, S20.	2.8	0
26	Characterization of bispecific antibodies that drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models. European Journal of Cancer, 2019, 110, S3.	2.8	0
27	SCIDOT-06. TOWARDS EXCLUSIVELY LOCAL THERAPY OF GLIOBLASTOMA - ENGINEERING IL-12Fc WITH SUPERIOR TISSUE RETENTION AND MINIMAL SYSTEMIC EXPOSURE AFTER CNS ADMINISTRATION. Neuro-Oncology, 2019, 21, vi273-vi273.	1.2	0
28	P09.10â€Local immunotherapy of brain cancer harnessing high-retention Fc-fusion constructs. , 2020, , .		0
29	Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways. Journal of Hepatology, 2020, 73, S175.	3.7	0
30	The need for speed: how PD1-blockade only works if T cells are properly activated. Translational Cancer Research, 2017, 6, S1018-S1021.	1.0	0
31	DDRE-48. COMPARTMENT LOCKED IL-12 - INCREASED TISSUE RETENTION AND MINIMAL PERIPHERAL EXPOSURE ALLOW HIGHER TREATMENT EFFICACY AND TOLERABILITY IN LOCAL GLIOBLASTOMA THERAPY. Neuro-Oncology, 2021, 23, vi85-vi85.	1.2	0